Propranolol
Also known as: Inderal
Beta Blocker | Heart Rate & Anxiety Management
Overview
Propranolol is a non-selective beta-adrenergic receptor antagonist (beta blocker) and one of the oldest and most widely prescribed drugs in its class. FDA-approved since 1967 and marketed as Inderal, it blocks both beta-1 receptors in the heart (reducing heart rate, contractility, and cardiac output) and beta-2 receptors in the bronchial and vascular smooth muscle. In the performance-enhancing drug community, propranolol serves two primary roles: managing elevated resting heart rate caused by compounds such as trenbolone and clenbuterol, and controlling performance anxiety or situational anxiety symptoms. Trenbolone is notorious for raising resting heart rate and causing nocturnal tachycardia, while clenbuterol directly stimulates beta-2 receptors to increase heart rate as part of its sympathomimetic action. Propranolol's non-selective beta blockade makes it effective against both mechanisms. Its rapid onset (within 30-60 minutes of oral dosing) and relatively short duration of action make it well-suited for as-needed use, though it can also be dosed regularly for sustained heart rate control throughout an AAS cycle.
Key benefits
- Rapid reduction of elevated heart rate within 30-60 minutes of oral dosing
- Effective against tachycardia from both trenbolone and clenbuterol through non-selective beta blockade
- Well-established anxiolytic effect for performance anxiety without cognitive impairment or sedation
- Short half-life allows flexible as-needed dosing without prolonged hemodynamic effects
- Extensive clinical safety data spanning over 50 years of use
- Inexpensive and widely available as a generic medication
- Does not cause dependence or withdrawal symptoms typical of benzodiazepines
- Effective for controlling physical anxiety symptoms (tremor, palpitations, sweating)
Mechanism of action
Propranolol competitively blocks both beta-1 and beta-2 adrenergic receptors. Beta-1 blockade in the sinoatrial node and myocardium reduces heart rate (negative chronotropy), decreases the force of cardiac contraction (negative inotropy), and slows atrioventricular conduction (negative dromotropy). This directly counteracts the tachycardia induced by sympathomimetic compounds like clenbuterol and the unexplained heart rate elevation commonly reported with trenbolone use. Beta-2 blockade in peripheral vasculature contributes to a modest increase in peripheral vascular resistance initially, though chronic use leads to a net reduction in blood pressure through decreased cardiac output and suppression of renin release from the juxtaglomerular cells. Propranolol is highly lipophilic, readily crossing the blood-brain barrier, which accounts for its efficacy in managing anxiety symptoms, essential tremor, and the physical manifestations of sympathetic nervous system activation (tremor, palpitations, sweating). This central penetration also explains why propranolol is more effective for anxiety-related indications than hydrophilic beta blockers like atenolol. The drug undergoes extensive first-pass hepatic metabolism via CYP2D6 and CYP1A2, resulting in variable bioavailability (approximately 25-35%).
Molecular data
- Type
- Aryloxypropanolamine derivative (C16H21NO2)
- Half-life
- ~4-5 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Heart Rate Management
Anxiety & Performance
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 10-40 mg | 30-60 minutes before event | — |
| — | 20-80 mg/day | Divided into 2-3 doses daily | — |
| — | 10-20 mg | 1-2 times daily (as needed with clen doses) | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Fatigue and reduced exercise tolerance, particularly during the first week of use
- Cold extremities (hands and feet) due to beta-2 blockade of peripheral vasodilation
- Bradycardia (heart rate below 60 bpm), usually dose-dependent and asymptomatic
- Dizziness or lightheadedness, especially when standing quickly
- Gastrointestinal discomfort (nausea, diarrhea, constipation)
Rare side effects
- Bronchospasm in individuals with asthma or reactive airway disease (due to beta-2 blockade)
- Masking of hypoglycemia symptoms (tachycardia, tremor) in insulin-dependent diabetics or those using exogenous insulin with GH
- Depression or mood changes with chronic use (controversial, but reported)
- Sexual dysfunction (erectile difficulties, decreased libido) at higher doses
- Raynaud's phenomenon or worsening of peripheral vascular disease
Contraindications
- Asthma or severe reactive airway disease (non-selective beta blockade can trigger life-threatening bronchospasm)
- Decompensated heart failure or cardiogenic shock
- Sinus bradycardia (resting HR below 50 bpm) or second/third-degree heart block
- Severe peripheral arterial disease or Raynaud's syndrome
- Pheochromocytoma without prior alpha blockade (risk of hypertensive crisis from unopposed alpha stimulation)
Monitoring
- Heart rate: regular monitoring, targeting resting HR of 60-80 bpm; hold dose if HR consistently below 55 bpm
- Blood pressure: monitor at baseline and regularly during use; watch for symptomatic hypotension
- Blood glucose: monitor in diabetic patients or those using insulin/GH, as propranolol masks hypoglycemia symptoms
- Respiratory status: assess for wheezing or dyspnea, especially in individuals with any history of airway reactivity
- Peripheral circulation: assess for cold extremities, color changes, or numbness in fingers and toes
References
Primary literature and clinical-trial data informing this entry.